Severe left ventricular systolic dysfunction after permanent pacemaker implantation: Should we pause before upgrading to biventricular pacing?

Debabrata Bera a, Sachin Yalagudri a, Soumen Devidutta a, Daljeet Kaur Saggua, Zakir Ali b, Calambur Narasimhana, *

a Dept of Electrophysiology, CARE Hospitals, Hyderabad, India
b Dept of Nuclear Medicine, Basavatarakam Indo-American Cancer Hospital, Hyderabad, India

ABSTRACT

Left ventricular (LV) systolic dysfunction leading to heart failure (HF) is known to occur after permanent pacemaker implantation (PPI) in a subset of patients. They are often treated by upgradation of the pacemaker to cardiac resynchronisation therapy (CRT). We report a case of progressive LV dysfunction and HF after PPI. Cardiac 18FDG-PET-CT scan revealed abnormal myocardial FDG uptake suggestive of cardiac sarcoidosis (CS). Biopsy from FDG avid lymph node demonstrated non-caseating granuloma. Therapy with steroids resulted in resolution of HF symptoms accompanied by a significant improvement in LV function.

Copyright © 2019, Indian Heart Rhythm Society. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Following PPI approximately 9% of patients develop significant LV dysfunction [1]. Right Ventricular (RV) pacing-induced cardiomyopathy (PICM) is defined as a 10% or more reduction in the LV ejection fraction (EF) after PPI, resulting in an EF of less than 45% [1,2]. Usually, new onset HF and LV dysfunction after implantation of a pacemaker is attributed to RV pacing induced dyssynchrony. In most instances, coronary angiogram is performed to exclude coronary artery disease and the device is upgraded to CRT. Majority improve following this intervention but approximately one-third remain in persistent HF [2].

Varying degree of LV dysfunction or AV block can be the initial presentation of occult CS [3,4]. It is a progressive disease and what presented as AV block may be followed by LV systolic dysfunction due to chronic inflammatory myocarditis in due course [5]. Unrecognized, such patients usually have upgradation to cardiac resynchronisation therapy (CRT) and some eventually have cardiac transplantation. Studies have shown that, worsening LV function and ventricular arrhythmia (VA) are preventable and might be reversed, if CS is treated early [6].

We report a case which illustrates that delay in diagnosis of CS in a patient with AV block resulted in severe LV dysfunction due to disease progression. Appropriate initiation of immunosuppression led in improvement of LV function and symptoms.

2. Case report

A 61 year-old gentleman underwent PPI for symptomatic AV block [complete heart block with a wide QRS [right bundle branch block (RBBB) morphology escape] [ Fig. 1A]. He had undergone aortic valve replacement (AVR) for severe calcific aortic stenosis 3 years back. He had normal LV systolic function on echocardiography (LVEF = 56%) during PPI.

Six months after PPI, he presented with progressive shortness of breath and HF (NYHA class IV). He had bilateral pedal oedema, elevated jugular venous pressure; with bi-basal crepitations. NT-pro BNP was elevated (1432 pg/mL). Echocardiography revealed severe LV dysfunction (LVEF had dropped to 37%) with increase in LV dimensions (LV internal diameter in diastole (LVIDd) 48→63 mm, LV internal diameter in systole (LVIDs) 40→52mm), grade III
mitral regurgitation (MR) and elevated pulmonary artery systolic pressure (PASP- 47 mm Hg). Device interrogation and electrocardiography (ECG) suggested 100% V pacing (As - Vp: 96%, Ap - Vp 4%) [Fig. 1B]. Medical therapy was optimized with adequate doses of angiotensin converting enzyme (ACE) inhibitor (ACEI), beta-blocker and mineralocorticoid receptor antagonist. He continued to remain symptomatic. He was considered for upgradation of device to biventricular pacing.

Over next one month, the LV function deteriorated further (LVIDd- 70 mm, LVIDs- 57 mm, LVEF 32%, PASP- 60 mm Hg). Such rapid deterioration of LV function over a short period (of 4 months) was unusual. Few cervical and axillary lymph nodes were palpable on physical examination. His ESR and hs-CRP were elevated. ESR was 78 mm/1st hour (haemoglobin was normal) and CRP was 60.6 mg/dL at the baseline. This was suggestive of something beyond RV pacing-induced cardiomyopathy. A cardiac $^{18}$FDG PET-CT scan was performed considering possibility of an inflammatory cardiomyopathy. It revealed significant abnormal myocardial (SUV max 8.1) as well as cervical, axillary and mediastinal lymph node FDG uptake (SUV max 7.5) highly suggestive of inflammatory cardiomyopathy [Fig. 2A,B,C]. The lymph node (LN) biopsy revealed non-caseating granuloma. Mantoux skin test, TB (Tuberculosis)-PCR and TB culture from the biopsy samples were negative. A diagnosis of cardiac sarcoidosis was made and he was started on oral steroid. His functional status improved to NYHA class II within 3 weeks of starting immunosuppression. Repeat PET-CT scan after 4 months showed significant reduction in FDG uptake (SUV max 2.0 in pre-tracheal LNs, no myocardial uptake). After 6 months of steroid therapy, his HF symptoms had completely resolved and LV function had improved (EF 50%). [Table 1].

At 1-year follow-up, he was asymptomatic, along with a near complete recovery of LV function (LVEF = 54%) and reduction of MR to grade I (without CRT). The third PET scan at 1 year showed completely absent FDG uptake (Fig. 2D,E,F).

3. Discussion

Sarcoidosis is a multisystem disease of unknown aetiology. Among patients with sarcoidosis, 5% have overt cardiac involvement, whereas additional 20% patients have unrecognized cardiac involvement [7]. Cardiac tuberculosis (CTB) is a close mimicker of CS and at times, it is difficult to differentiate these two entities [8,9]. The common presentations of CS/CTB is VA, LV dysfunction and AV block. They can present in isolation or in combination [8 – 10]. With different manifestations in the same patient, there may be a temporal separation among them like AV block preceding LV dysfunction or vice versa [9]. As they usually do not have systemic symptoms, the underlying granulomatous myocarditis (GM) is often missed and the disease keeps smoldering.

Our case highlights that a subset of patients who develop HF symptoms and/or LV dysfunction after PPI, may actually have underlying GM/CS even though RV-PICM is the commonest cause for
the same. Early recognition and treatment of underlying CS can prevent progressive LV dysfunction, reduce morbidity and mortality as well as prevent unnecessary device upgrading or cardiac transplantation. Some authors [5,11,12] have also reported similar cases, where underlying CS rather than PICM which was responsible for progressive LV dysfunction. It is indeed difficult to suspect CS among patients diagnosed of PICM as majority of do not have systemic involvement. Detailed clinical examination (like enlarged lymph nodes) and monitoring acute phase reactants can provide clues to the underlying aetiology.

Conflicts of interest

None.

Acknowledgement

We extend our regards to Mrs. Swapna Nalla and Mrs. Venkat laxmi Lavishetty who helped us in collecting the data and developing the images and manuscript.

References

[1] Yu CM, Chan JY, Zhang Q, Omar R, Yap GW, Hussin A, et al. Biventricular pacing in patients with bradycardia and normal ejection fraction. N Engl J Med 2009;361:2123—34.
[2] Dreger H, Maethner K, Bondke Hansjürgen, Baumann G, Melzer Christoph. Pacing-induced cardiomyopathy in patients with right ventricular stimulation for >15 years. EP Europace 1 February 2012;14(Issue 2):238—42.
[3] Rajani R, Prasad S, O’Nunain S, Sohal M, Ghuran A. Heart block: a primary manifestation of sarcoidosis. EP Europace 1 February 2010;12(Issue 2):284—8.
[4] Danwade TA, Devidutta S, Shetke AB, Saggu DK, Vyagudri SD, Sridevi C, et al. Prognostic value of fluorine-18 fluoro-2-deoxyglucose positron emission computed tomography in patients with unexplained atrioventricular block. Heart Rhythm 2018 Feb;15(2):234—9.
[5] Fororat H, Rowe MK, Koczy D, Kaye G. Cardiac sarcoidosis, left ventricular impairment and chronic right ventricular pacing: pacing or pathology? Heart Lung Circ 2017;26(11):1175—82.
[6a] Padala S, Peasley S, Siddu M, Steckman D, Judson M. Impact of early initiation of corticosteroid therapy on cardiac function and rhythm in patients with cardiac sarcoidosis. Int J Cardiol 2017;227:565—70.
[6b] Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 1978;58:1204—11.
[7] Matsui Y, Iwai K, Tachibana T, et al. Clinicopathological study on fatal myocardial sarcoidosis. Ann N Y AcadSci1976; 278: 455—469
[8] Hulten E, Aalam S, Osborne M, Abbott S, Bittencourt M, Blankstein R. Cardiac sarcoidosis—state of the art review. Cardiovasc Diagn Ther 2016 Feb;6(1):50—63.
[9] Rose AG. Cardiac tuberculosis. A study of 19 patients. Arch Pathol Lab Med 1987 May;111(5):422—6.
[10] Nery P, Beanlands R, Nair G, Green M, Yang J, Mcardl B, Davis D, Ohira H, Goble M, leung e, healey j. Binnie d H. Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults. J Cardiovasc Electrophysiol 2014;25:875—81. https://doi.org/10.1111/jce.12401.
[11] Wakabayashi Y, Mitsuhashi T, Akashi N, Hayashi T, Umemoto T, Sugawara Y, Fujita H, Momomura S. Clinical characteristics associated with pacing-induced cardiac dysfunction: a high incidence of undiagnosed cardiac sarcoidosis before permanent pacemaker implantation. Heart Vessel 2018;33(12):1505—14.
[12] Kaida T, Inomata T, Minami Y, Yazaki M, Fujita T, Iida Y, Ikeda Y, Nabe T, Ishit S, Naruke T, Maekawa E, Kostabash T, Ako J. Importance of early diagnosis of cardiac sarcoidosis in patients with complete atrioventricular block. Int Heart J 2018 Jul 31;59(4):772—8. 10.1536.

Table 1

Showing the serial echocardiographic parameters.

| Timeline                                      | LVIDd (mm) | LVIDs (mm) | LVEF (Modified Simpsons) (%) | Mitral regurgitation grade | PASP (mm of Hg) |
|----------------------------------------------|------------|------------|-----------------------------|----------------------------|-----------------|
| At pacemaker Implantation                     | 48         | 40         | 56                          | I                          | 30              |
| After 4 months of PPI                         | 63         | 52         | 37                          | III                        | 47              |
| After another 1 month (When steroid was finally started) | 70         | 57         | 32                          | II                         | 60              |
| After 6 Months of starting steroid           | 53         | 43         | 50                          | I                          | 32              |

Fig. 2. A, B, C- Significant myocardial and lymph node uptake at presentation. D, E, F- Complete resolution of FDG uptake after 1 year.